Loss-of-function mutations in SLC30A8 protect against type 2 diabetes

被引：354

作者：

Flannick, Jason ^{[1
,2
,3
]}

Thorleifsson, Gudmar ^{[4
]}

Beer, Nicola L. ^{[1
,5
]}

Jacobs, Suzanne B. R. ^{[1
]}

Grarup, Niels ^{[6
]}

Burtt, Noel P. ^{[1
]}

Mahajan, Anubha ^{[7
]}

Fuchsberger, Christian ^{[8
]}

Atzmon, Gil ^{[9
,10
]}

Benediktsson, Rafn ^{[11
]}

Blangero, John ^{[12
]}

Bowden, Don W. ^{[13
,14
,15
,16
]}

Brandslund, Ivan ^{[17
,18
]}

Brosnan, Julia ^{[19
]}

Burslem, Frank ^{[20
]}

Chambers, John ^{[21
,22
,23
]}

Cho, Yoon Shin ^{[24
]}

Christensen, Cramer ^{[25
]}

Douglas, Desiree A. ^{[26
]}

Duggirala, Ravindranath ^{[12
]}

Dymek, Zachary ^{[1
]}

Farjoun, Yossi ^{[1
]}

Fennell, Timothy ^{[1
]}

Fontanillas, Pierre ^{[1
]}

Forsen, Tom ^{[27
,28
]}

Gabriel, Stacey ^{[1
]}

Glaser, Benjamin ^{[29
,30
]}

Gudbjartsson, Daniel F. ^{[4
]}

Hanis, Craig ^{[31
]}

Hansen, Torben ^{[6
,32
]}

Hreidarsson, Astradur B. ^{[11
]}

Hveem, Kristian ^{[33
]}

Ingelsson, Erik ^{[7
,34
]}

Isomaa, Bo ^{[35
,36
]}

Johansson, Stefan ^{[37
,38
,39
]}

Jorgensen, Torben ^{[40
,41
,42
]}

Jorgensen, Marit Eika ^{[43
]}

Kathiresan, Sekar ^{[1
,44
,45
,46
]}

Kong, Augustine ^{[4
]}

Kooner, Jaspal ^{[22
,23
,47
]}

Kravic, Jasmina ^{[48
]}

Laakso, Markku ^{[49
,50
]}

Lee, Jong-Young ^{[51
]}

Lind, Lars ^{[52
]}

Lindgren, Cecilia M. ^{[1
,7
]}

Linneberg, Allan ^{[40
,41
,42
,53
]}

Masson, Gisli ^{[4
]}

Meitinger, Thomas ^{[54
]}

Mohlke, Karen L. ^{[55
]}

Molven, Anders ^{[37
,56
,57
]}

机构：

[1] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02141 USA

[2] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA

[3] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA

[4] Amgen Inc, deCODE Genet, Reykjavik, Iceland

[5] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England

[6] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn,Ctr Basic Metab Res, Copenhagen, Denmark

[7] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England

[8] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA

[9] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA

[10] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10467 USA

[11] Landspitali Univ Hosp, Dept Endocrinol & Metab, Reykjavik, Iceland

[12] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA

[13] Wake Forest Univ, Bowman Gray Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC USA

[14] Wake Forest Univ, Bowman Gray Sch Med, Ctr Diabet Res, Winston Salem, NC USA

[15] Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC USA

[16] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC USA

[17] Vejle Hosp, Dept Clin Biochem, Vejle, Denmark

[18] Univ Southern Denmark, Inst Reg Hlth Res, Odense, Denmark

[19] Pfizer Inc, Cardiovasc & Metab Dis Res Unit, Cambridge, MA USA

[20] Prescient Life Sci, Cardiovasc & Metab Dis Practice, London, England

[21] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London, England

[22] Univ London Imperial Coll Sci Technol & Med, Healthcare Natl Hlth Serv NHS Trust, London, England

[23] Ealing Hosp NHS Trust, Southall, Middx, England

[24] Hallym Univ, Dept Biomed Sci, Chunchon, South Korea

[25] Vejle Hosp, Dept Internal Med & Endocrinol, Vejle, Denmark

[26] Lund Univ, Dept Clin Sci, Unit Diabet & Celiac Dis, Malmo, Sweden

[27] Univ Helsinki, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland

[28] Vaasa Hlth Care Ctr, Diabetes Care Unit, Vaasa, Finland

[29] Hadassah Hebrew Univ, Med Ctr, Endocrinol & Metab Serv, Jerusalem, Israel

[30] IDRG, Holon, Israel

[31] Univ Texas Hlth Sci Ctr Houston, Human Genet Ctr, Houston, TX 77030 USA

[32] Univ Southern Denmark, Fac Hlth Sci, Odense, Denmark

[33] Norwegian Univ Sci & Technol, Fac Med, Dept Publ Hlth, Levanger, Norway

[34] Uppsala Univ, Dept Med Sci, Mol Epidemiol & Sci Life Lab, Uppsala, Sweden

[35] Folkhalsan Res Ctr, Helsinki, Finland

[36] Dept Social Serv & Hlth Care, Pietarsaari, Finland

[37] Univ Bergen, KG Jebsen Ctr Diabet Res, Dept Clin Sci, Bergen, Norway

[38] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway

[39] Univ Bergen, Dept Biomed, Bergen, Norway

[40] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark

[41] Univ Copenhagen, Fac Hlth & Med, Copenhagen, Denmark

[42] Aalborg Univ, Fac Med, Aalborg, Denmark

[43] Steno Diabet Ctr, DK-2820 Gentofte, Denmark

[44] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA

[45] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Div Cardiol, Boston, MA 02114 USA

[46] Harvard Univ, Sch Med, Dept Med, Boston, MA USA

[47] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, NHLI, London, England

[48] Lund Univ, Ctr Diabet, Dept Clin Sci Diabet & Endocrinol, Malmo, Sweden

[49] Univ Eastern Finland, Dept Med, Kuopio, Finland

[50] Kuopio Univ Hosp, SF-70210 Kuopio, Finland

来源：

NATURE GENETICS | 2014年 / 46卷 / 04期

基金：

芬兰科学院; 英国惠康基金; 瑞典研究理事会; 美国国家卫生研究院; 欧洲研究理事会;

关键词：

ZINC TRANSPORTER ZNT8; GENOME-WIDE ASSOCIATION; GLUCOSE-HOMEOSTASIS; COMMON VARIANTS; BETA-CELL; INSULIN; RARE; PATHOPHYSIOLOGY; EXPRESSION; RESPONSES;

D O I：

10.1038/ng.2915

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Loss-of-function mutations protective against human disease provide in vivo validation of therapeutic targets1-3, but none have yet been described for type 2 diabetes (T2D). Through sequencing or genotyping of -150,000 individuals across 5 ancestry groups, we identified 12 rare protein-truncating variants in SLC30A8, which encodes an islet zinc transporter (ZnT8) 4 and harbors a common variant (p. Trp325Arg) associated with T2D risk and glucose and proinsulin levels5-7. Collectively, carriers of protein-truncating variants had 65% reduced T2D risk (P = 1.7 x 10(-6)), and non-diabetic Icelandic carriers of a frameshift variant (p. Lys34Serfs* 50) demonstrated reduced glucose levels (-0.17 s. d., P = 4.6 x 10(-4)). The two most common proteintruncating variants (p. Arg138* and p. Lys34Serfs* 50) individually associate with T2D protection and encode unstable ZnT8 proteins. Previous functional study of SLC30A8 suggested that reduced zinc transport increases T2D risk(8,9), and phenotypic heterogeneity was observed in mouse Slc30a8 knockouts(10-15). In contrast, loss-of-function mutations in humans provide strong evidence that SLC30A8 haploinsufficiency protects against T2D, suggesting ZnT8 inhibition as a therapeutic strategy in T2D prevention.

引用

页码：357 / +

页数：8

共 50 条

[41] Contribution of SLC30A8 variants to the risk of type 2 diabetes in a multi-ethnic population: a case control study
Salem, Sameer D.
Saif-Ali, Riyadh
Ismail, Ikram S.
Al-Hamodi, Zaid
Muniandy, Sekaran
BMC ENDOCRINE DISORDERS, 2014, 14
[42] Association of SLC30A8 gene polymorphism with type 2 diabetes, evidence from 46 studies: a meta-analysis
Mengdi Fan
Weimin Li
Lian Wang
Suping Gu
Sisi Dong
Mengdie Chen
Haimin Yin
Jinjue Zheng
Xiaoying Wu
Jian Jin
Xuchao Jiang
Jiao Cai
Peining Liu
Chao Zheng
Endocrine, 2016, 53 : 381 - 394
[43] A prospective study of dietary and supplemental zinc intake and risk of type 2 diabetes depending on genetic variation in SLC30A8
Drake, Isabel
Hindy, George
Ericson, Ulrika
Orho-Melander, Marju
GENES AND NUTRITION, 2017, 12
[44] Association between SLC30A8 rs13266634 Polymorphism and Type 2 Diabetes Risk: A Meta-Analysis
Cheng, Liqing
Zhang, Dongmei
Zhou, Lina
Zhao, Jie
Chen, Bing
MEDICAL SCIENCE MONITOR, 2015, 21 : 2178 - 2189
[45] Zinc transporter 8 (SLC30A8) and diabetes:: a promising new diagnostic and therapeutic target
Seve, Michel
METAL IONS IN BIOLOGY AND MEDICINE, VOL 10, 2008, 10 : 727 - 730
[46] Autoantibodies to Zinc Transporter 8 and SLC30A8 Genotype in Type 1 Diabetes Childhood: A Pioneering Study in North Africa
Fakhfakh, Raouia
Kmiha, Sana
Tahri, Safa
Feki, Sawsan
Zouidi, Ferjeni
Abida, Olfa
Hachicha, Mongia
Kammoun, Thouraya
Masmoudi, Hatem
JOURNAL OF DIABETES RESEARCH, 2022, 2022
[47] Association between R325W zinc transporter-8 gene polymorphism (SLC30A8) and Type 2 diabetes
Lee, Yong Ho
Kang, Eun Seok
Kim, So Hun
Han, Seung Jin
Hur, Kyu Yeon
Kim, Chul Hoon
Ahn, Chul Woo
Cha, Bong Soo
Nam, Moonsuk
Lee, Hyun Chul
DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 79 : S29 - S30
[48] Impact of an SLC30A8 loss-of-function variant on the pancreatic distribution of zinc and manganese: laser ablation-ICP-MS and positron emission tomography studies in mice
Firth, George
Georgiadou, Eleni
Griffiths, Alexander
Amrahli, Maral
Kim, Jana
Yu, Zilin
Hu, Ming
Stewart, Theodora J.
Leclerc, Isabelle
Okamoto, Haruka
Gomez, Daniel
Blower, Philip J.
Rutter, Guy A.
FRONTIERS IN ENDOCRINOLOGY, 2023, 14
[49] Association of a SLC30A8 Genetic Variant with Monotherapy of Repaglinide and Rosiglitazone Effect in Newly Diagnosed Type 2 Diabetes Patients in China
JIANG Feng 1
Biomedical and Environmental Sciences, 2012, 25 (01) : 23 - 29
[50] SLC30A8 gene polymorphism (rs13266634 C/T) and type 2 diabetes mellitus in south Iranian population
Faghih, Hossein
Khatami, Saied-Reza
Azarpira, Negar
Foroughmand, Ali-Mohammad
MOLECULAR BIOLOGY REPORTS, 2014, 41 (05) : 2709 - 2715

← 1 2 3 4 5 →